Hoth Therapeutics (HOTH, Financial) is advancing its lead treatment, HT-001, by engaging Premier Research to assist in submitting an Expanded Access Program (EAP) application. This initiative aims to provide cancer patients, who experience severe skin toxicities from epidermal growth factor receptor (EGFR) inhibitor therapies, access to HT-001. This condition represents an area with significant unmet medical need. Early evaluations suggest HT-001 offers clinical benefits, and Hoth is now preparing to offer this investigational drug to eligible patients not enrolled in ongoing clinical trials.
The EAP, commonly referred to as "compassionate use," is a crucial regulatory option for patients who cannot participate in standard clinical trials and have no approved treatment alternatives. Through this program, Hoth aspires to make HT-001 accessible to patients, thereby addressing an urgent medical challenge.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Hoth Therapeutics Inc (HOTH, Financial) is $4.50 with a high estimate of $5.00 and a low estimate of $4.00. The average target implies an upside of 260.00% from the current price of $1.25. More detailed estimate data can be found on the Hoth Therapeutics Inc (HOTH) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Hoth Therapeutics Inc's (HOTH, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
